Skip to content
Review Open access

The economic value of mismatch repair–guided immunotherapy in endometrial cancer: companion testing and patient selection

Sep 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 40 references
Medicine

Abstract

Mismatch repair (MMR) status has moved from hereditary-cancer screening to a central predictive biomarker for immunotherapy in endometrial cancer. The marked difference in treatment benefit between MMR-deficient/microsatellite instability-high (dMMR/MSI-H) and MMR-proficient/microsatellite-stable (pMMR/MSS) tumors creates an economic rationale for companion testing, but the value of testing depends on assay accuracy, treatment price, duration, survival extrapolation, and local willingness-to-pay thresholds. This Mini Review examines the clinical and economic value of MMR-guided immunotherapy in advanced and recurrent endometrial cancer. A targeted literature search of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from database inception through 31 July 2026. We summarize practical testing pathways based on four-protein immunohistochemistry, reflex mutL homolog 1 (MLH1) promoter methylation, MSI assays, and selective next-generation sequencing; review MMR-stratified evidence from major immunotherapy trials; and compare published cost-effectiveness analyses of pembrolizumab, dostarlimab, atezolizumab, durvalumab-based regimens, and pembrolizumab plus lenvatinib. Across studies, dMMR/MSI-H disease generally generates the largest quality-adjusted survival gains and the most favorable incremental cost-effectiveness ratios, whereas the economic case in pMMR/MSS disease is more sensitive to drug pricing and modeling assumptions. Overall, MMR testing can function as an allocation technology that prioritizes high-value treatment, while future work should harmonize testing, manage discordant results, refine biomarkers for pMMR tumors, and incorporate long-term survival, quality of life, equity, and value of information into economic models.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.